Europe continues to battle counterfeiters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe continues to battle counterfeiters
Governments, regulators and international agencies continue to defend against counterfeiters; in particular, the European Commission has outlined measures that may help to better regulate pharmaceutical distributors. There is still much work to be done, however, particularly when it comes to counterfeit drugs sold via the internet.


Pharmaceutical Technology Europe
Volume 21, Issue 12

References

1. IMS Health, IMS Health Market Prognosis (2009). http://www.imshealth.com/

2. European Federation of Pharmaceutical Industries and Associations, "Combating counterfeit medicines and protecting patients through a partnership approach" (2005). http://www.efpia.eu/

3. Europa, "Protecting the legal supply chain against counterfeited medicines" (2008). http://europa.eu/

4. International Narcotics Control Board, "INCB warns of counterfeit medicines flooding markets" (2007). http://www.incb.org/

5. Europe Economics, "Policies to Combat Counterfeit Medicines: Contribution to Impact Assessment" (2008). http://www.europe-economics.com/

6. Partnership for Safe Medicines, "Counterfeit Drugs in Europe" (2005). http://www.safemedicines.org/

7. European Federation of Pharmaceutical Industries and Associations, "Zero tolerance for counterfeit medicines" (2009). http://www.efpia.eu/

8. European Commission, "Summary of responses to the public consultation document on a legislative proposal to combat counterfeit medicines for human use" (2008). http://ec.europa.eu/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here